TNFRSF17 and plasma cell myeloma: CT103A represents a promising BCMA-directed CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma, with robust clinical efficacy and the potential to address the unmet medical needs of patients with advanced disease.